CONTROL-MYOPIA
Financiado
Myopia control in the real world: treatments, target, timing, and terminus
Background:
Myopia, or near-sightedness, is increasing dramatically all over the world, mostly due to higher levels of education and changing lifestyles of young generations. The expectation is that half of the world’s citizens w...
Background:
Myopia, or near-sightedness, is increasing dramatically all over the world, mostly due to higher levels of education and changing lifestyles of young generations. The expectation is that half of the world’s citizens will be myopic by 2050. Myopia-related complications later in life are a serious threat to vision and will increase the rates of blindness. Prevention strategies and pharmacological and optical treatments to delay progression of myopia in childhood are emerging, but most eye care professionals still do not control myopia due to inadequate information and unpredictable outcomes.
Aim:
To radically improve patient management in myopia by providing an agile, AI-based clinical decision support system stooled on a solid scientific basis of integrated multidisciplinary data.
Approach:
1. To construct population-based reference centiles for eye growth and progression of myopia for screening and surveillance of myopia in young generations in Europe
2. To capture high-quality, long-term, prospective data from the real world on myopia control, and specifically gain evidence on timing, effectiveness, side effects, and acceptability of current treatment modalities in daily practice
3. To investigate patient profiles for poor response and adherence to myopia control
4. To predict the final outcome of myopia based on a plethora of potential predictors using advanced machine learning techniques
5. To develop the CONTROL-MYOPIA platform with a user-centred and highly interactive design which provides an accurate prediction of myopia outcomes with and without myopia control, and which recommends the right prevention and treatment for the right patient at the right time
Impact:
CONTROL-MYOPIA’s outcomes will have widespread impact on clinical care, patient participation, public health, design of clinical trials, research innovation, and policy changes
ver más
Duración del proyecto: 60 meses
Fecha Inicio: 2023-09-20
Fecha Fin: 2028-09-30
Fecha Fin: 2028-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-20
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5